# Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

Study · id `cardio:ct-nct07190690` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07190690](<https://clinicaltrials.gov/study/NCT07190690>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07190690

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2100 participants.

## Technical summary

Registry record NCT07190690. Randomized; no masking; primary purpose treatment. Start 2025-12-19 (actual); primary completion 2029-10-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 2100 participants (planned count; ClinicalTrials.gov record NCT07190690, source copy `cardio:ctgov-nct07190690-2026-08-10`, retrieved 2026-10-26)
- Started: 2025-12-19 (actual) (ClinicalTrials.gov record NCT07190690, source copy `cardio:ctgov-nct07190690-2026-08-10`, retrieved 2026-10-26)
- Primary completion: 2029-10-15 (anticipated) (ClinicalTrials.gov record NCT07190690, source copy `cardio:ctgov-nct07190690-2026-08-10`, retrieved 2026-10-26)
- Completion: 2030-10-15 (anticipated) (ClinicalTrials.gov record NCT07190690, source copy `cardio:ctgov-nct07190690-2026-08-10`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT07190690, source copy `cardio:ctgov-nct07190690-2026-08-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07190690-2026-08-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions
- Acronym: DestinACSion
- Condition: Coronary Artery Disease
- Intervention (Device): ihtDEStiny® DES implanted
- Intervention (Device): Xience™ DES implanted
- Lead sponsor: Fundación EPIC
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Fundación EPIC (`cardio:org-fundacion-epic`)

## Provenance

Content hash: 21e660aae68d0e2ab1c090d5f33b81ac79b59d9d077798633695b11257f456ac
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
